Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US

Ralph P. Insinga, David J. Vanness, Josephine L. Feliciano, Kristel Vandormael, Sory Traore, Flavia Ejzykowicz, Thomas Burke

Research output: Contribution to journal › Article › peer-review

60 Scopus citations

Fingerprint

Dive into the research topics of 'Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US'. Together they form a unique fingerprint.

Medicine & Life Sciences